Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Harvard Apparatus Regenerative Technology had a gross margin of 8.85% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Harvard Apparatus Regenerative Technology Gross Margin % Related Terms
Harvard Apparatus Regenerative Technology Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HRGN vs DTEAF, STCB, JVA: Gross Margin % Comparison
For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Apparatus Regenerative Technology Gross Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Harvard Apparatus Regenerative Technology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Harvard Apparatus Regenerative Technology (HRGN) has a Gross Margin % of 8.85% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Harvard Apparatus Regenerative Technology and its competitors. This is 61% below median its historical median of 22.73. According to the industry distribution chart, Harvard Apparatus Regenerative Technology ranks #1719 out of 1899 companies in the Consumer Packaged Goods industry, placing it in the top 90.5%.
Is Harvard Apparatus Regenerative Technology's Gross Margin % too high?
Harvard Apparatus Regenerative Technology's current Gross Margin % of 8.85% is 61% below median its 10-year median of 22.73. The Consumer Packaged Goods industry median Gross Margin % is 26.37. Harvard Apparatus Regenerative Technology's value of 8.85% is 66.4% below this industry median. Based on the distribution chart, Harvard Apparatus Regenerative Technology ranks #1719 out of 1899 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's Gross Margin % compare to DTEAF and STCB?
According to the Consumer Packaged Goods industry distribution chart, Harvard Apparatus Regenerative Technology ranks #1719 out of 1899 companies for Gross Margin %. This places Harvard Apparatus Regenerative Technology in the lower half of its industry. The industry median Gross Margin % is 26.37. Harvard Apparatus Regenerative Technology's value of 8.85% is 66.4% below this benchmark. While the company's 10-year median is 22.73 vs. the industry median of 26.37, Harvard Apparatus Regenerative Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Consumer Packaged Goods company?
The median Gross Margin % among Consumer Packaged Goods companies is 26.37, based on 1,899 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Apparatus Regenerative Technology's current Gross Margin % of 8.85% is 66.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Harvard Apparatus Regenerative Technology and its competitors. For the Consumer Packaged Goods industry, the median Gross Margin % is 26.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Apparatus Regenerative Technology's current Gross Margin % is 8.85%, which is 61% below median its own 10-year median of 22.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology (HRGN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.34, compared to a current price of $1.04 — trading 80.5% below its estimated fair value. The current Gross Margin % is 8.85%, which is 61% below median its 10-year median of 22.73 and 66.4% below the Consumer Packaged Goods industry median of 26.37. Harvard Apparatus Regenerative Technology's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current Gross Margin % is 8.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Apparatus Regenerative Technology (HRGN) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology stock appears to be undervalued.
The current stock price of $1.04 is trading 80.5% below its estimated GF Value™ of $5.34.
GuruFocus considers Harvard Apparatus Regenerative Technology to be Possible Value Trap.
Key valuation signals for HRGN:
Gross Margin %: 8.85% (61% below median its 10-year median of 22.73)
GF Value™: $5.34 vs. price of $1.04 (80.5% below fair value)
Industry Position: 66.4% below the Consumer Packaged Goods median (#1719 of 1899)
No single metric tells the full story. See the HRGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Apparatus Regenerative Technology Business Description
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
33GF Score
Get the complete analysis for HRGN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRGN has been successfully added to your 
